McDermott and Bull executive Search
 

Other News

IMDS Launches NHanceIT™ Microcatheter in the U.S. to Advance Complex PCI

Coronary/Structural Heart by 0 comments

RODEN, Netherlands–(BUSINESS WIRE)–Interventional Medical Device Solutions (IMDS), a specialty catheter company developing purpose-built solutions for complex PCI, CHIP, and CTO procedures, today announced the U.S. launch of NHanceIT™, an over-the-wire, single-lumen microcatheter built on proprietary Skeleton Backbone™ technology. Engineered to improve lesion crossing in challenging coronary anatomy, NHanceIT is part of the IMDS portfolio designed to address distinct procedural challenges thr

Continue Reading →

Epsilon Health Raises $27.6 Million to Solve America’s Growing Radiologist Shortage

Financial Radiology by 0 comments

SAN FRANCISCO–(BUSINESS WIRE)–Epsilon Health (“Epsilon”), the AI-native radiology practice reinventing how radiology is delivered, today emerged from stealth with $27.6 million in funding led by AlleyCorp, with participation from Uncork Capital, Renegade Partners, SemperVirens, and Jack Altman, who invested while serving as Managing Partner at Alt Capital. Epsilon is tackling one of the most urgent crises in American healthcare.Medical imaging is a foundational pillar of the U.S. healthcare sy

Continue Reading →

SS Innovations Provides Update on Continuing Progress and Milestones

Financial by 0 comments

— Advancing global expansion, pediatric robotic surgery and telesurgery — — Growing SSi Mantra installations, procedures and utilization — FORT LAUDERDALE, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) — via IBN — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today provided an update on the Company’s continuing progress and milestones. Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “Our advanced, cost-effective SSi Mantra surgical robotic system (the “SSi Mantra”) is benefitting lives globally, one patient at a time, from a 45-day old baby needing kidney surgery in India to a cardiac patient in Sri Lanka.  Our progress in democratizing access to state-of-the-art surgical robotic care continues to be reflected in growing SSi Mantra installations, procedures and utilization.” Recent Company Progress and Milestones: Global Expansion Colombia.  On July 29, 2026, Dr. Sudhir Srivastava officially launched the robotic cardiac surgery program at La Fundación Cardiovascular de Colombia (FCV) in Bucaramanga, Colombia, performing the country’s first Totally Endoscopic Beating-Heart Bypass Surgery using the SSi Mantra surgical robotic system.  Sri Lanka.  On August 23, 2026, Kings Hospital Colombo installed the first SSi Mantra surgical robotic system in Sri Lanka, marking the official launch of the medical center’s robotic surgery program. Following its installation at Kings Hospital, the SSi Mantra has been utilized to perform the country’s first robotic-assisted cardiac surgery and over 25 other robotic surgeries within the first three weeks of operation.  Global Installed Base.  With the installation in Sri Lanka, the SSi Mantra’s global installed base now spans 12 countries, including a leading presence in the Company’s immense home market of India. US and EU Regulatory Review. Looking ahead, SS Innovations expects that the U.S. Food and Drug Administration will complete its review of the Company’s 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027 and believes that a European Union CE marking certification can be obtained by the end of 2026. Pediatric Robotic Surgery  Intricate Robot-Assisted Pediatric Surgery.  On August 14, 2026, the Company’s SSi Mantra surgical robotic system and 5-millimeter instrumentation were utilized by Dr. M. Ramalingam to perform a robotic pyeloplasty on a 45-day-old baby at Hindusthan Hospital in Coimbatore, India. The infant recovered rapidly after successful completion of the complex yet minimally invasive kidney procedure. This accomplishment represents another proof point for the SSi Mantra’s capabilities in pediatric robotic surgery, which involves the smallest patients and requires superior precision and control during suturing and cutting, among other surgical tasks.   Cumulative Pediatric Surgeries. As of August 31, 2026, a total of 258 pediatric robotic surgeries have been completed with the SSi Mantra.  Robotic Telesurgery  Longest-Distance Telesurgery.  On July 29, 2026, a team of surgeons led by Dr. Sudhir Srivastava utilized the SSi Mantra to perform a successful robotic telesurgery between Colombia and India, spanning more than 13,600 miles (22,000 kilometers) of fiber network distance and eclipsing the previous longest-distance telesurgery record also held by the Company.  The telesurgery, a robotic sleeve gastrectomy, was performed remotely from Hospital Internacional de Colombia in Bucaramanga, Colombia on a patient located at Mohak Bariatrics and Robotics in Indore, India. Expanding Ecosytem in India.  On August 9, 2026, Ahmedabad, India-based Shalby Hospital joined an expanding ecosystem of healthcare institutions utilizing the SSi Mantra to perform robotic-assisted telesurgery. Three surgical procedures were successfully performed remotely from SS Innovations’ headquarters in Gurugram, India, more than 590 miles (950 kilometers) from the patients at Shalby Hospital. Launch of Telesurgery in the Philippines. On September 5, 2026, the SSi Mantra was used to perform the first telesurgery within the Philippines between Pampanga and Cotabato, a distance of approximately 1,070 miles (1,710 kilometers).   Cumulative Telesurgeries.  As of August 31, 2026, a total of 188 robotic telesurgeries have been completed with the SSi Mantra. Increasing Utilization and Scale 50 Robot-Assisted Surgeries in a Single Day.  On August 15, 2026, the surgical team at Mohak Bariatrics and Robotics in Indore, India utilized five separate SSi Mantra systems to successfully complete 50 robotic general surgery procedures in a single day, demonstrating the robustness of the Company’s technology.  Practice and Hospital Milestones. Numerous practices and hospitals across India and abroad are surpassing the 200+, 100+ and 50+ procedure milestones with the SSi Mantra, indicating growing utilization and ability to scale. Growing Installations and Procedures More than 14,000 Successful Procedures.  As of September 8, 2026, the SSi Mantra cumulative installed base totaled 238, up 42% from 168 at the end of 2025 and the number of multi-specialty procedures completed with the SSi Mantra totaled 14,103, up 79% from 7,885 at the end of 2025.  Broad Pool of Surgeon Users. To date, approximately 1,500 physicians have been trained on the SSi Mantra, which has been utilized to perform over 170 different types of surgical procedures. About SS Innovations SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery.  Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.  Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates. About the SSi MantraThe SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that provides equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 170 different types of surgical procedures. Forward Looking StatementsThis press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investor Contact:The Equity Group        Kalle Ahl, CFA              T: (303) 953-9878        kalle.ahl@theequitygroup.com Devin Sullivan, Managing Director T: (212) 836-9608devin.sullivan@theequitygroup.com Media Contact:RooneyPartners LLCKate BarretteT: (212) 223-0561kbarrette@rooneypartners.com Corporate Communications: IBNAustin, TexasIBN.Ai512.354.7000 OfficeEditor@IBN.Ai

Continue Reading →

XCath Robotics Receives FDA Breakthrough Device Designation for the Iris System for Remote Robotic-Assisted Mechanical Thrombectomy in Acute Ischemic Stroke

Peripheral/Endo Regulatory by 0 comments

HOUSTON–(BUSINESS WIRE)–XCath Robotics, a medical device company advancing endovascular surgical robotics, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its Iris Surgical Robotic System for remote robotic-assisted mechanical thrombectomy in patients with acute ischemic stroke. The FDA’s Breakthrough Devices Program is designed to support the development of medical devices that have the potential to provide more effective treatment f

Continue Reading →

Kestra Names Daniel Finney Vice President of Research & Development

Financial by 0 comments

KIRKLAND, Wash., Sept. 10, 2026 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, announced today that Daniel Finney has been named Vice President of Research & Development and appointed to the company’s executive leadership team. “Research and development is central to advancing our mission and expanding the role of wearable protection for at-risk patients during critical periods of recovery,” said Brian Webster, President and Chief Executive Officer. “The Cardiac Recovery System® platform was designed from the outset to evolve. Dan’s hands-on role in developing the ASSURE® WCD, together with his technical depth, product experience, and demonstrated leadership, positions him to guide our next phase of innovation and extend the platform’s value for patients and providers.” Mr. Finney succeeds Phillip D. Foshee, Jr., who led Kestra’s research and development organization from 2016 until his recent retirement. During his nearly decade-long tenure, Mr. Foshee spearheaded the development of the ASSURE WCD and helped establish the technical foundation on which Kestra continues to build. The appointment comes as Kestra advances an integrated product strategy across the Cardiac Recovery System platform. Building on its extensible architecture, Mr. Finney will lead initiatives spanning internal research and development, strategic partnerships, and the application of AI, with priorities informed by clinical evidence and real-world insights from patients and clinicians. This evidence base includes findings from the ASSURE Clinical Evaluation Post-Approval Study (ACE-PAS), the largest prospective real-world study of wearable cardioverter defibrillators conducted to date. “It has been incredibly rewarding to be part of the team that brought the ASSURE WCD from concept to market and to see firsthand its impact on patients and its role in expanding the wearable defibrillator category,” said Mr. Finney. “That experience gives me confidence in the strength and potential of the Cardiac Recovery System platform. I’m genuinely excited about our vision and roadmap, and I look forward to leading this team as we advance the next generation of wearable cardiac protection.” Mr. Finney has more than 20 years of experience in Class III medical device development, engineering management, and project management. Most recently, he served as Kestra’s Senior Director of New Product Development, leading engineering teams and product development initiatives. Before joining Kestra, he held product development roles with Stryker, Physio-Control, and Medtronic. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com.  Forward-Looking StatementsExcept where otherwise noted, the information contained in this press release is as of April 22, 2026. Statements in this press release that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; and other risks and uncertainties, including those described under the heading “Risk Factors” in Kestra’s Annual Report on Form 10-K for the fiscal year ended April 30, 2026 filed with the U.S. Securities and Exchange Commission (“SEC”) on July 14, 2026, and in other periodic reports filed by Kestra with the SEC. These filings are available on the Investor Relations section of our website at https://investors.kestramedical.com/ and on the SEC’s website at https://sec.gov/. CONTACT: Media contact 
Rhiannon Pickus 
rhiannon.pickus@kestramedical.com 

Investor contact 
Neil Bhalodkar 
neil.bhalodkar@kestramedical.com 

Continue Reading →

Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology

Financial by 0 comments

CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM) today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to receive an award of up to $9.5 million to build the first autonomous clinical AI agent capable of providing safe and effective care to patients suffering from heart failure. Funding provided through ARPA-H’s ADVOCATE (Agentic AI-EnableD CardioVascular CAre TransfOrmati

Continue Reading →

Implicity secures $40M growth equity funding to scale its AI-driven cardiac monitoring platform globally

Financial by 0 comments

The round is led by growth fund IRIS alongside Five Arrows. Funding will fuel Implicity’s next phase of growth in the US through local commercial hires, build on its established leadership across Europe, and accelerate further AI investment. Implicity already serves over 250 medical centers and monitors 120,000+ patients daily […]

Continue Reading →

Medicana Uses Robot-Assisted Technology to Perform Heart Surgery Through Small Ports

Coronary/Structural Heart by 0 comments

Medicana Health Group’s Prof. Suat Büket, MD explains how selected bypass and heart-valve procedures can be completed without dividing the breastbone while maintaining the same surgical objective Photo: Robotic heart surgery at Medicana Health Group via FL Comms ISTANBUL, Sept. 09, 2026 (GLOBE NEWSWIRE) — For selected heart patients, complex surgery can now be performed through several small openings between the ribs rather than by dividing the breastbone. Robot-assisted cardiac surgery combines a surgeon-controlled console with high-definition three-dimensional imaging, tremor filtration and highly articulated instruments, offering a minimally invasive route to procedures that have traditionally required a full sternotomy. Prof. Suat Büket, MD, a cardiovascular surgeon at Medicana Health Group, said the most important point is often misunderstood: the robot does not perform the operation independently. “The surgeon remains in control at every stage. The system translates the surgeon’s hand movements into precise movements inside the chest. Its value lies in giving us a magnified three-dimensional view and a range of motion that is difficult to achieve with conventional instruments through a small opening,” said Prof. Büket. Photo: Prof. Suat Büket, MD via FL Comms Several small ports instead of a divided breastbone In conventional open-heart surgery, access to the heart often requires a midline incision and division of the sternum. The bone is then rejoined at the end of the operation and must heal over the following weeks, during which patients may face movement restrictions. Wound and bone-healing complications can be particularly challenging for patients with certain risk factors. In robot-assisted cardiac surgery, the surgical team can access the chest through three or four ports between the ribs, each approximately one centimetre, depending on the planned operation. A camera and the robotic instruments are introduced through these openings. The surgeon operates from a console in the operating theatre while the bedside team supports the procedure. Technology expands the surgeon’s view and reach The system’s high-definition camera provides a three-dimensional, magnified view of the operative field. Wristed instruments can bend and rotate beyond the range of the human hand, while computer-assisted tremor filtration supports steady movement. These features are designed to help the surgeon work precisely in confined anatomical spaces; they do not replace clinical judgement or the surgical team. The robot is a surgical instrument — not an autonomous decision-maker. Patient selection, operative planning and every surgical movement remain the responsibility of the trained clinical team. The surgical objective does not change Prof. Büket stressed that a minimally invasive approach should not mean a reduced operation. When robot-assisted surgery is clinically appropriate, the aim is to complete the same planned cardiac repair or revascularisation that would otherwise be performed through an open approach. “If the plan is to perform bypass grafting or repair or replace a heart valve, the objective remains the same. The difference is the route we use to reach the heart. A smaller incision must never mean an incomplete procedure,” he said. Recovery benefits depend on the right patient Avoiding sternotomy may reduce the burden of bone healing and allow some patients to return to everyday movement sooner. Smaller incisions may also reduce wound-related concerns and can offer cosmetic and psychosocial benefits. However, not every patient is a candidate. The decision depends on the planned procedure, anatomy, previous operations, vascular access and the findings of pre-operative tests. “Robotic cardiac surgery is not automatically the best option simply because the incisions are smaller,” Prof. Büket said. “The safest and most effective approach is selected after a complete assessment. Technology adds value when it is matched to the right patient, the right procedure and an experienced team.” From precision tools to connected operating rooms Robot-assisted surgery also points toward a more connected future for operating theatres. Research into remote surgical support and telesurgery continues, but current practice still depends on a trained surgical team, specialist infrastructure and direct clinical oversight. For Prof. Büket, the immediate priority is not distance but precision: using the technology available today to reduce surgical trauma without compromising the completeness or safety of the operation. About Medicana Health Group Founded in 1992, Medicana Health Group is one of Türkiye’s leading privately owned healthcare providers, operating 19 hospitals in Türkiye, the United Kingdom, and Bosnia and Herzegovina. Serving more than 5 million patients annually, including a significant international patient base, Medicana delivers multidisciplinary care across a broad range of specialties with a strong focus on clinical excellence and patient-centered service. In addition to healthcare, the Group invests in education through Medicana Education Group and Fenerbahçe University. With approximately 15,000 employees, Medicana continues to expand its international footprint while advancing sustainability through renewable energy investments and supporting Turkish sports through long-term health sponsorships. Media contact Uğur AlkaparGlobal Media Relations DirectorFL Communicationsugur@flcommunications.co.uk This press release is intended for general informational purposes. Treatment decisions must be made by qualified clinicians following an individual patient assessment. Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7b10f86c-bc1f-41a5-a99e-3a5afb79b174 https://www.globenewswire.com/NewsRoom/AttachmentNg/92e8455e-008d-4a4a-9c60-1b85de881324

Continue Reading →
1 2 3 … 1,372